Given the strong binding affinities observed in our study, targeting MiR-155 or its interactions with PTEN, SOCS1, and BCL-6 may serve as a potential therapeutic intervention for VEGF-driven CRC progression [84, 90]. The gene discussed is BCL6; the disease is colorectal carcinoma.